Oncology is a therapeutic area going through fundamental changes. These changes – driven by macroeconomic, competitive and scientific factors – are taking us many steps closer to making cancer a chronic condition, while keeping the overall cost of care within manageable boundaries.  

The impact of these changes is being felt across the industry and by every player involved. The overall care ecosystem is feeling the need to evolve, innovate and grow.  

The paper highlights macro and micro factors affecting oncology and proposes a partnership-driven framework to catalyze innovation for oncology-focused biopharma. It also identifies the high-impact technologies that will affect the entire value-chain of cancer research and care delivery.

Download whitepaper

Harshal Shah
Head of Oncology Innovations, Global Medical Technology

Harshal is part of our global medical division based out of Boston, with more than a decade of experience in medical device development, product life cycle strategy, and innovation management. He has significant expertise in oncology patient journey, economics of cancer care and innovations in oncology. He has a Bachelor of Mechanical Engineering degree from Nirma Institute of Technology in India, an MBA from Syracuse University, New York, and he recently completed a post graduate program in cancer biology and therapeutics development from Harvard Medical School.